148 related articles for article (PubMed ID: 35860862)
1. Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.
Salerno SN; Deng R; Kakkar T
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1316-1327. PubMed ID: 35860862
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab.
Jordan SC; Kucher K; Bagger M; Hockey HU; Wagner K; Ammerman N; Vo A
Am J Transplant; 2020 Sep; 20(9):2581-2588. PubMed ID: 32301258
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
[TBL] [Abstract][Full Text] [Related]
5. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
Jin F; Tayab ZR; Balthasar JP
AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia.
Deng R; Balthasar JP
J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194
[TBL] [Abstract][Full Text] [Related]
9. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.
Simon DI; Xu H; Ortlepp S; Rogers C; Rao NK
Arterioscler Thromb Vasc Biol; 1997 Mar; 17(3):528-35. PubMed ID: 9102172
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
Song S; Crow AR; Freedman J; Lazarus AH
Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.
Crow AR; Yu H; Han D; Lazarus AH
PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
[TBL] [Abstract][Full Text] [Related]
13. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants.
Malik PRV; Edginton AN
J Clin Pharmacol; 2020 Apr; 60(4):466-476. PubMed ID: 31729044
[TBL] [Abstract][Full Text] [Related]
14. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.
Zhu D; Ravindranath MH; Terasaki PI; Miyazaki T; Pham T; Jucaud V
Clin Exp Immunol; 2014 Aug; 177(2):464-77. PubMed ID: 24611451
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.
Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK
Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura.
Hansen RJ; Balthasar JP
J Pharmacol Exp Ther; 2001 Jul; 298(1):165-71. PubMed ID: 11408538
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.
Hansen RJ; Balthasar JP
Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736
[TBL] [Abstract][Full Text] [Related]
19. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.
Crow AR; Song S; Semple JW; Freedman J; Lazarus AH
Br J Haematol; 2001 Dec; 115(3):679-86. PubMed ID: 11736954
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
Gold HK; Gimple LW; Yasuda T; Leinbach RC; Werner W; Holt R; Jordan R; Berger H; Collen D; Coller BS
J Clin Invest; 1990 Aug; 86(2):651-9. PubMed ID: 2384607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
